2026, Pharmacokinetics, Therapies and Treatment

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2026

Pharmacokinetics

Therapies

Treatment

New data validates tau silencing gene therapy for Alzheimer’s

Drug Discovery World

FEBRUARY 23, 2024

Voyager Therapeutics has announced new data from its two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease. Based on these data, Voyager has advanced this programme into late research and expects to file an investigational new drug (IND) application in 2026.

Therapies

Therapies Pharmacokinetics RNA International

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation.

Vaccine

Vaccine Therapies Trials Clinical Trials

Analysis Life Sciences Thank You 166 guidance documents the FDA is actively working on in 2024 (and beyond)

Agency IQ

FEBRUARY 15, 2024

We have tried to sort guidance documents by topic area.

FDA

FDA Science Biosimilars Production

Drug Discovery Digest

New data validates tau silencing gene therapy for Alzheimer’s

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

Analysis Life Sciences Thank You 166 guidance documents the FDA is actively working on in 2024 (and beyond)

Stay Connected